46 136

Cited 0 times in

Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node-positive, HER2-positive breast cancer

Authors
 Chihwan Cha  ;  Sung Gwe Ahn  ;  Dooreh Kim  ;  Janghee Lee  ;  Soeun Park  ;  Soong June Bae  ;  Jee Ye Kim  ;  Hyung Seok Park  ;  Seho Park  ;  Seung Il Kim  ;  Byeong-Woo Park  ;  Joon Jeong 
Citation
 INTERNATIONAL JOURNAL OF CANCER, Vol.149(8) : 1585-1592, 2021-10 
Journal Title
INTERNATIONAL JOURNAL OF CANCER
ISSN
 0020-7136 
Issue Date
2021-10
MeSH
Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized / administration & dosage ; Antineoplastic Combined Chemotherapy Protocols / therapeutic use* ; Axilla ; Biomarkers, Tumor ; Breast Neoplasms / drug therapy* ; Breast Neoplasms / metabolism ; Breast Neoplasms / pathology ; Female ; Follow-Up Studies ; Gene Expression Regulation, Neoplastic ; Humans ; Lymph Nodes / metabolism ; Lymph Nodes / pathology* ; Lymphatic Metastasis ; Middle Aged ; Neoadjuvant Therapy / methods* ; Prognosis ; Receptor, ErbB-2 / antagonists & inhibitors* ; Receptor, ErbB-2 / metabolism* ; Retrospective Studies ; Survival Rate ; Trastuzumab / administration & dosage
Keywords
HER2-positive breast cancer ; axillary response ; neoadjuvant therapy ; pertuzumab ; trastuzumab
Abstract
Incorporating dual human epidermal growth factor receptor 2 (HER2) blockade into neoadjuvant systemic therapy (NST) led to higher response in patients with HER2-positive breast cancer. However, axillary response to treatment regimens, including single or dual HER2 blockade, in patients with clinically node-positive breast cancer remains uncertain. Our study aimed to examine the pathologic axillary response according to the type of NST, that is, single or dual HER2 blockade. In our study, 546 patients with clinically node-positive, HER2-positive breast cancer who received NST followed by axillary surgery were retrospectively selected and divided into three groups: chemotherapy alone, chemotherapy + trastuzumab and chemotherapy + trastuzumab with pertuzumab. The primary outcome was the axillary pathologic complete response (pCR). Among 471 patients undergoing axillary lymph node dissection, the axillary pCR rates were 43.5%, 74.5% and 68.8% in patients who received chemotherapy alone, chemotherapy + trastuzumab and chemotherapy + trastuzumab with pertuzumab, respectively. There was no difference in axillary pCR rates between patients who received single or dual HER2 blockade (P = .379). Among patients receiving chemotherapy + trastuzumab, patients without breast pCR had the greatest risk for residual axillary metastases (relative risk, 9.8; 95% confidence interval, 3.2-14.9; P < .0001). In conclusion, adding trastuzumab to chemotherapy increased the axillary pCR rate in patients with clinically node-positive, HER2-positive breast cancer; furthermore, dual HER2-blockade with trastuzumab and pertuzumab did not elevate the axillary response compared with trastuzumab alone. Breast pCR could be a strong predictor for axillary pCR in clinically node-positive patients treated with HER2-targeting therapy.
Files in This Item:
T202103587.pdf Download
DOI
10.1002/ijc.33726
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Seung Il(김승일)
Kim, Jee Ye(김지예) ORCID logo https://orcid.org/0000-0003-3936-4410
Park, Byeong Woo(박병우) ORCID logo https://orcid.org/0000-0003-1353-2607
Park, Se Ho(박세호) ORCID logo https://orcid.org/0000-0001-8089-2755
Park, So Eun(박소은)
Park, Hyung Seok(박형석) ORCID logo https://orcid.org/0000-0001-5322-6036
Bae, Soong June(배숭준) ORCID logo https://orcid.org/0000-0002-0012-9694
Ahn, Sung Gwe(안성귀) ORCID logo https://orcid.org/0000-0002-8778-9686
Jeong, Joon(정준) ORCID logo https://orcid.org/0000-0003-0397-0005
Cha, Chi Hwan(차치환)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/185374
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links